ライフサイエンスコーパス: drug carrier

1 , thus making them promising candidates as a drug carrier.

2 GCF following its release from beta-TCP as a drug carrier.

3 delivery in bone with temperature-sensitive drug carriers.

4 n in vivo, indicating their potential use as drug carriers.

5 increase the exposure of tumor cells to ELP drug carriers.

6 conductors, cosmetics, microelectronics, and drug carriers.

7 e-permeabilizing agents and nanomaterials as drug carriers.

8 mpatible and biomimetic materials as well as drug carriers.

9 rties, which may be relevant to their use as drug carriers.

10 als become quenched upon being released from drug carriers.

11 rapeutics; however, GNPs have limitations as drug carriers.

12 effective exosome-based or exosome-mimicking drug carriers.

13 agents for magnetic resonance imaging and as drug carriers.

14 b) were evaluated as potential nutraceutical/drug carriers.

15 t uniquely position them as highly effective drug carriers.

16 pear preferable to those with solid cores as drug carriers.

17 ective cell interactions make them promising drug carriers.

18 g peptides (CPPs) are promising molecules as drug carriers.

19 at rationale for the trend toward nano-sized drug carriers.

20 rget a temperature-responsive macromolecular drug carrier, an elastin-like polypeptide (ELP) to solid

21 ent cells respond differentially to the same drug carrier, an important factor that should be conside

22 rived FDA approved material (beeswax) as the drug carrier and fenofibrate as the drug.

23 tion that have been successfully employed as drug carriers and biomaterials in several applications.

24 mes have now progressed beyond simple, inert drug carriers and can be designed to be highly responsiv

25 tically evaluate the status of dendrimers as drug carriers and find answers as to why this class of c

26 se rates have on the efficacy of synergistic drug carriers and motivate the use of HA as a delivery p

27 eterogeneous transport behavior of submicron drug carriers and pathogens in biological environments.

28 mide conjugates merit further development as drug carriers and radioimaging agents.

29 erials field for use as diagnostic reagents, drug carriers, and tissue engineering scaffolds.

30 Red blood cells (RBCs) based drug carrier appears to be the most appealing for protei

31 to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged activation o

32 In this approach, drug carriers are modified with targeting ligands that c

33 These drug carriers are passively targeted to tumors through t

34 S to analyze drug penetration of a liposomal drug carrier as well as its metabolites.

35 discussed in this review, include serving as drug carriers, as targeting ligands, and as protease-res

36 for anchoring of drug conjugates and bulkier drug carriers, as well as proper signaling for uptake wi

37 The drug-carrier association after intravenous administratio

38 tion recently because of their simple use as drug carrier at human body temperature.

39 e other hand, development of multifunctional drug carriers at the 'nano'-scale is providing exciting

40 he importance of rapid drug release from the drug carriers at the tumor site.

41 thod describes advanced tailoring of polymer drug carriers based on polymer-block-peptides.

42 rm basis for the development of EVs as smart drug carriers based on straightforward and transferable

43 magnetic fields with the electric forces in drug-carrier bonds to enable remotely controlled deliver

44 hybrid nanogels in nanomedicine, not only as drug carriers but also as imaging and theranostic agents

45 ata with CD44TA-SMP, we anticipate that this drug carrier can open new avenues in TB management.

46 of EVs to liposomes and vice versa, improved drug carriers can be developed which will advance the fi

47 The size and shape of nanoparticle (NP) drug carriers can potentially be manipulated to increase

48 g the utility of enzyme-responsive nanoscale drug carriers capable of targeted accumulation and reten

49 s and binding epitopes must be accessible to drug carriers, carriers must be free of harmful effects,

50 ould be employed to model the release of any drug-carrier combination.

51 ET imaging to systematically investigate how drug-carrier compatibility affects drug release in a tum

52 these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing op

53 Here, we synthesized a nanoparticle-based drug carrier composed of chitosan, UA and folate (FA-CS-

54 ications ranging from waterborne coatings to drug-carrier-delivery systems.

55 This technology represents a novel drug carrier designed to prolong the presence of bioacti

56 hile not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common

57 d other nano-sized constructs are attractive drug carriers due to their extended plasma circulation;

58 hase-transfer catalysts, and multifunctional drug carriers, each of which benefits from opposing surf

59 ension, grafting of antioxidant molecules to drug carriers enables a dual-function mechanism to effec

60 Furthermore, drug carriers face additional challenges in their transl

61 ment of solid tumors, systemically delivered drug carriers face significant challenges that are impos

62 to test the usefulness of serum albumin as a drug carrier for corneal disorders.

63 in this work extend the concept of a general drug carrier for loading both positively and negatively

64 A novel nanoparticle-based drug carrier for photodynamic therapy is reported which

65 y of non-ionic surfactants currently used as drug carriers for antibiotic, anti-inflammatory, and ant

66 of widely used surfactants currently used as drug carriers for antibiotic, anti-inflammatory, and ant

67 Ts are increasingly being explored as potent drug carriers for cancer treatment, for biosensing, and

68 esicles, or liposomes, have been employed as drug carriers for decades, resulting in several approved

69 Silica nanoparticles (SiNPs) are promising drug carriers for ophthalmic drug delivery.

70 tial of using ceramic-based nanoparticles as drug carriers for photodynamic therapy has been demonstr

71 nhances tumor imaging, and the addition of a drug carrier function to the particles is envisioned.

72 Drug carriers generally fail to provide superior efficac

73 To determine if this class of drug carriers has potential applications in vivo, FSI/Ra

74 Various liposomal drug carriers have been developed to overcome short plas

75 y lacking therapy, in part because drugs and drug carriers have no natural endothelial affinity.

76 These novel inhalable silk-based drug carriers have the potential to be used as anti-canc

77 dispensed for the potential that nano-sized drug carriers hold.

78 Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments

79 mulation of a thermally responsive polymeric drug carrier in solid tumors over a single heat-cool cyc

80 ) to enhance the penetration of nanoparticle drug carriers in convection-enhanced delivery (CED).

81 DEAdcCE-caged peptide sequences as selective drug carriers in the context of photocontrolled targeted

82 ntial in applications such as cell-cell/cell-drug carrier interaction studies and rapid screening of

83 e introduction of an additional mechanism of drug/carrier interaction.

84 ttempts were made to target microparticulate drug carriers into cytoplasm bypassing the endocytotic p

85 eficient the translation of these nano-sized drug carriers into the clinical setting is.

86 A modern multi-functional drug carrier is critically needed to improve the efficac

87 The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of th

88 A novel anti-cancer drug carrier, mesenchymal stem cells (MSCs) encapsulatin

89 -isopropylacrylamide) (PNIPAm), as a general drug carrier model for controlled drug release.

90 ate endohedral complexes as superconductors, drug carriers, molecular reactors, and ferroelectric mat

91 o-electric nanoparticles as field-controlled drug carriers offer a unique capability of field-trigger

92 routinely used as a surfactant to formulate drug carriers, on the transport of nanoparticles in fres

93 at hydrophobin might be a powerful tool as a drug carrier or a pH sensitive drug-release compound.

94 e quantum rattles significantly enhanced the drug-carrier performance of the silica shell.

95 etism of gold quantum dots, and enhances the drug-carrier performance of the silica shell.

96 s silica nanoparticles (SiNPs) are promising drug carrier platforms for intraocular drug delivery.

97 We encapsulated the drug carrier pPB-HSA, which specifically binds to the PD

98 Inorganic nanoparticles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, and

99 In conclusion, the development of an "ideal" drug carrier should involve the optimization of both dru

100 These multimodal nanocomposite drug carriers should be ideal for selective intra-arteri

101 control the intratumor distribution of these drug carriers should improve vascular-specific delivery.

102 Nanoparticulate drug carriers such as liposomal drug delivery systems ar

103 We demonstrated that relatively large drug carriers, such as 200-nm liposomes, can also be del

104 sub-cellular level is a desired feature of a drug carrier system.

105 very of antibiotics with novel biodegradable drug carrier systems, such as the gentamicin-collagen im

106 nds (e.g., enzymes, antibodies, peptides) to drug carrier systems.

107 abilized immunoliposomes (anti-HER2 SL) as a drug carrier targeting HER2-overexpressing cancers.

108 the first time as a magnetically responsive drug carrier that can serve both as a magnetic resonance

109 A new micelle drug carrier that consists of a diblock polymer of propy

110 le and highlight the advantages of a natural drug carrier that demonstrates reduced cellular toxicity

111 ncirculating, biodegradable s.c. implants as drug carriers that are stable throughout the duration of

112 improve the delivery of existing drugs with drug carriers that can manipulate when, where, and how a

113 systems is hampered by the lack of suitable drug carriers that respond sharply to visible light stim

114 promising applications as imaging probes and drug carriers that target cancer cells for cytoplasmic c

115 When designing drug carriers, the drug-to-carrier ratio is an important

116 amer-conjugated multistage vector (ESTA-MSV) drug carrier to bone marrow for the treatment of breast

117 elf-assembling protein, was first applied as drug carrier to stabilize GLP-1 against protease degrada

118 suggests that HALs may be a useful targeted drug carrier to treat CD44-expressing tumors.

119 are coated onto balloons using excipients as drug carriers to facilitate adherence and release of dru

120 to the necessity of developing site-specific drug carriers to improve the delivery of molecular medic

121 To develop drug carriers to macrophages, it is important to underst

122 ight into the development of new transdermal drug carriers to treat a variety of skin disorders.

123 h as gene targeting vectors and encapsulated drug carriers (typical range, 100-300 nm) into tumors.

124 tro studies using tumor cells to investigate drug-carrier uptake and destruction of cancer cells by p

125 ng direct periadventitial delivery without a drug carrier was published prior to 2000.

126 both small dye molecules and large liposomal drug carriers were quantified using fluorescence microsc

127 aim of this work was to develop a nanoscale drug carrier, which could be loaded with an anti-cancer

128 model for optimizing the pharmacokinetics of drug carriers who's circulatory half-life is dependent i

129 density nature of most biomaterials used as drug carriers will result in very low fractions of the a

130 Developing a drug carrier with favorable handling characteristics tha

131 on and applicable to fabricating particulate drug carriers with desired size and shape.

132 tool that has facilitated the development of drug carriers with enhanced penetration of mucus, brain

133 ng avenues for the design of multifunctional drug carriers with extreme control over their physico-ch

134 cent advances achieved by combining drugs or drug carriers with NIR light responsive plasmonic nanoma

135 capsule engineering can lead to well-defined drug carriers with unique properties (139 references).

136 n in the mouse stomach compared with passive drug carriers, with no apparent toxicity.